From the 1Scientific Institute of Public Health, Brussels, Belgium; 2European Cancer Network, IARC, Lyon, France; 3Laboratoire Pasteur-Cerba, Cergy Pontoise, France; 4Laboratory of Pathology, PAMM Laboratories, Eindhoven, the Netherlands; 5Central Lancashire Teaching Hospitals, Preston, United Kingdom; and 6Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
See related editorial on page 2.
Supported by the European Commission (Directorate of SANCO, Luxembourg, Grand-Duché du Luxembourg) through the European Network for Cervical Cancer Screening and the European Cancer Network, the DWTC/SSTC (Federal Service for Science, Culture and Technology, Brussels, Belgium), the Gynaecological Cancer Cochrane Review Collaboration (Bath, United Kingdom), and the Institute for the Promotion of Innovation by Science and Technology in Flanders (Brussels, Belgium).
The authors thank Dr. G. Ronco (CPO Piemonte, Torino, Italy) for provision of additional data.
Corresponding author: Marc Arbyn, Unit of Cancer Epidemiology, Scientific Institute of Public Health, J. Wytsmanstreet 14, B150 Brussels, Belgium; e-mail: [email protected].
Financial Disclosure The authors have no potential conflicts of interest to disclose.
